 |
|
|
| |
HIV-1 Attachment Inhibitor Prodrug BMS-663068: Assessment of Interactions with
Raltegravir in Treatment-Experienced HIV-1-Infected Subjects & Efficacy/Safety
|
| |
| |
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV and Hepatitis
Therapy; May 26-28, 2015; Washington, DC, USA.
I Landry,1 D Cui,2 J Wang,1 M Lataillade,3 DW Boulton1
CROI: 48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation - (03/03/15)
CROI: Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 48 Analysis - (02/27/15)
CROI: HIV-1 Attachment Inhibitor Prodrug BMS-663068: Interactions with DRV/r and/or ETR - (02/26/15)
CROI: HIV-1 Attachment Inhibitor Prodrug BMS-663068: Pharmacokinetics, Pharmacodynamics and Model-Based Dose Selection - (02/26/15)
CROI: BMS-955176: Antiviral Activity and Safety of a Second-Generation HIV-1 Maturation Inhibitor - (02/27/15)
CROI: Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in Preventing Viral Replication via Different Mechanism of Action Than Current Therapies - (02/27/15)
IDSA/2014: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis.......http://www.natap.org/2014/IDSA/IDSA_08.htm
Glasgow/2014: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis and Safety Profile - oral presentation......http://www.natap.org/2014/GLASGOW/GLASGOW_16.htm
HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Primary Week 24 Analysis of Emergent Drug Resistance.....http://www.natap.org/2014/ResisWksp/ResisWksp_08.htm
Glasgow/2014: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis.....http://www.natap.org/2014/GLASGOW/GLASGOW_17.htm
Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis......http://www.natap.org/2014/GLASGOW/GLASGOW_13.htm
Early studies - Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects.......http://www.natap.org/2012/HIV/090712_02.htm
|
| |
|
|
|
|
|
